Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.drreddys.com | |
Market Cap | 99,134.26 Cr. | |
Enterprise Value(EV) | 97,171.46 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 313.41 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 18.96 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 40.73 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 1,611.04 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 3.69 | Calculated using Price: 5,942.65 |
Dividend Yield | 0.67 | Period Ending 2023-03 |
No. of Shares Subscribed | 16.68 Cr. | 166,818,266 Shares |
FaceValue | 5 | |
About Dr. Reddy's Laboratories Ltd. | ||
The company is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations. |
1 Day |
|
-0.28% |
1 Week |
|
-3.52% |
1 Month |
|
-6.27% |
3 Month |
|
+5.18% |
6 Month |
|
+4.70% |
1 Year |
|
+20.95% |
2 Year |
|
+38.69% |
5 Year |
|
+112.17% |
10 Year |
|
+132.50% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 26.63 | 18.95 | 10.2 | 7.4 | 14.75 | 13.76 | 11.82 | 11.93 | 21.36 | |
Return on Capital Employed (%) | 22.7 | 19.55 | 9.77 | 8.21 | 13.66 | 11.12 | 15.49 | 14.59 | 26.22 | |
Return on Assets (%) | 13.67 | 11.05 | 6.14 | 4.23 | 8.86 | 9.2 | 8.21 | 8.08 | 15.01 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 9,853 | 12,570 | 12,262 | 12,572 | 14,024 | 15,599 | 17,642 | 19,212 | 23,286 | 25,497 | |
Non Curr. Liab. | 1,678 | 877 | 456 | 2,538 | 2,113 | -808 | -197 | -508 | -278 | -167 | |
Curr. Liab. | 6,821 | 6,347 | 8,420 | 6,894 | 5,897 | 7,214 | 8,104 | 9,766 | 8,572 | 8,407 | |
Minority Int. | |||||||||||
Equity & Liab. | 18,353 | 19,794 | 21,138 | 22,004 | 22,034 | 22,005 | 25,548 | 28,470 | 31,580 | 33,736 | |
Non Curr. Assets | 6,476 | 8,000 | 11,454 | 11,505 | 10,924 | 9,406 | 10,998 | 10,682 | 11,264 | 11,997 | |
Curr. Assets | 11,877 | 11,794 | 9,684 | 10,498 | 11,110 | 12,599 | 14,535 | 17,788 | 20,316 | 21,740 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 18,353 | 19,794 | 21,138 | 22,004 | 22,034 | 22,005 | 25,548 | 28,470 | 31,580 | 33,736 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 15,023 | 15,568 | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 27,213 | |
Other Income | 275 | 295 | 172 | 155 | 338 | 621 | 291 | 485 | 1,056 | 844 | |
Total Income | 15,298 | 15,863 | 14,368 | 14,436 | 15,786 | 18,138 | 19,339 | 22,030 | 25,725 | 28,056 | |
Total Expenditure | -11,530 | -11,983 | -11,724 | -11,930 | -12,270 | -15,047 | -15,178 | -17,778 | -18,321 | -19,585 | |
PBIDT | 3,769 | 3,880 | 2,644 | 2,506 | 3,516 | 3,091 | 4,161 | 4,252 | 7,405 | 8,471 | |
Interest | -109 | -83 | -63 | -79 | -89 | -98 | -97 | -96 | -143 | -147 | |
Depreciation | -760 | -939 | -1,027 | -1,077 | -1,135 | -1,163 | -1,229 | -1,165 | -1,250 | -1,418 | |
Taxation | -563 | -751 | -297 | -438 | -386 | 140 | -932 | -879 | -1,541 | -1,697 | |
Exceptional Items | |||||||||||
PAT | 2,336 | 2,108 | 1,257 | 912 | 1,950 | 2,026 | 1,952 | 2,183 | 4,507 | 5,209 | |
Minority Interest | |||||||||||
Share Associate | 23 | 35 | 34 | 19 | |||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 2,336 | 2,131 | 1,292 | 947 | 1,950 | 2,026 | 1,952 | 2,183 | 4,507 | 5,228 | |
Adjusted EPS | 137 | 125 | 78 | 57 | 117 | 122 | 117 | 131 | 271 | 314 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 1,970 | 2,524 | 3,263 | 2,144 | 1,803 | 2,870 | 2,984 | 3,570 | 2,811 | 5,888 | |
Cash Fr. Inv. | -1,694 | -2,265 | -2,039 | -1,840 | -1,488 | -773 | -492 | -2,266 | -2,639 | -4,137 | |
Cash Fr. Finan. | -24 | -433 | -1,700 | -369 | -444 | -2,133 | -2,516 | -30 | -242 | -2,686 | |
Net Change | 251 | -174 | -477 | -65 | -129 | -35 | -24 | 1,275 | -70 | -936 | |
Cash & Cash Eqvt | 862 | 583 | 492 | 378 | 254 | 223 | 196 | 1,482 | 1,485 | 578 |
Fri, 19 Apr 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Earnings call notification for Q4 FY 2024- Revised |
Fri, 19 Apr 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release |
Fri, 19 Apr 2024
Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Year Ended March 31 2024 Certiifcate under Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the year ended March 31 2024 |
Fri, 19 Apr 2024 |
High Delivery Percentage |
Higher Delivery Quantity |
Higher Delivery Quantity and Percentage |
Higher Trade Quantity |
Higher Trade and Delivery Quantity |